CD Protein Inhibitors 

  Products    Products    Diseases    News 


«12...6566676869707172737475...39323933»
  • ||||||||||  varnimcabtagene autoleucel (ARI-0001) / August Pi i Sunyer Biomedical Research Institute
    Journal, CAR T-Cell Therapy:  CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD: Clinical and Immunologic Follow-Up for 1 Year. (Pubmed Central) -  Aug 6, 2024   
    This observational study suggests that Rituximab is well tolerated and potentially effective therapy in a cohort of patients with symptomatic and progressive FM. This clinical case shows that CD19-directed CAR T-cell therapy is well-tolerated and is a potential treatment for patients with refractory MOGAD.
  • ||||||||||  Kimmtrak (tebentafusp-tebn) / Immunocore
    Biomarker, Journal:  GP100 expression is variable in intensity in melanoma. (Pubmed Central) -  Aug 6, 2024   
    For example, Tebentafusp, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, has generated significant enthusiasm in recent years due to its success in improving outcomes for uveal melanoma and is being studied in cutaneous melanoma...Using a quantitative immunofluorescence method, we confirmed the variability in expression. As gp100-binding drugs are assessed in clinical trials, the association between activity of the drugs and the level of gp100 expression should be studied in order to potentially improve patient selection.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
    Retrospective data, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker:  Clinical features associated with immune checkpoint inhibitor nephritis: a single-center clinical case series. (Pubmed Central) -  Aug 6, 2024   
    Our case series demonstrates that AKI from immune checkpoint inhibitors has a variable presentation that may require an individualized treatment approach. Further studies are needed to identify biomarkers that may help identify those at risk and guide the management of this condition.
  • ||||||||||  Nplate (romiplostim) / Amgen, Kyowa Kirin, Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Roche
    Review, Journal:  Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management. (Pubmed Central) -  Aug 6, 2024   
    Although IVIGand prednisone usually suffice to achieve hemostasis for delivery, second-lineagents are sometimes required to allow for neuraxial anesthesia. There isgrowing evidence supporting the use of romiplostim during pregnancy; however,its risk of venous thromboembolism warrants further evaluation.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Padcev (enfortumab vedotin-ejfv) / Astellas, Pfizer
    Journal:  SDRIFE und bull (Pubmed Central) -  Aug 6, 2024   
    There isgrowing evidence supporting the use of romiplostim during pregnancy; however,its risk of venous thromboembolism warrants further evaluation. No abstract available
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal, Post-transplantation:  Cutaneous Post-transplant Lymphoproliferative Disorder. (Pubmed Central) -  Aug 6, 2024   
    No abstract available We report a case of a 36-year-old male cardiac transplant recipient on long-term immunosuppression (ciclosporin, azathioprine, and prednisolone) who presented with a three-month history of a painless ulcer on the right lower leg. A skin biopsy showed a dermal atypical lymphoid infiltrate positive for PAX5, CD20
  • ||||||||||  Rituxan (rituximab) / Roche
    Journal:  Prospective study of the effect of rituximab on kidney function in membranous nephropathy. (Pubmed Central) -  Aug 6, 2024   
    We report a case of a 36-year-old male cardiac transplant recipient on long-term immunosuppression (ciclosporin, azathioprine, and prednisolone) who presented with a three-month history of a painless ulcer on the right lower leg. A skin biopsy showed a dermal atypical lymphoid infiltrate positive for PAX5, CD20 Rituximab was well tolerated; patient survival was 95.6% at 2
  • ||||||||||  Libtayo (cemiplimab-rwlc) / Regeneron
    Journal, Monotherapy:  Pseudoprogression of cutaneous squamous cell carcinoma invading the super vermillion border following programmed death-1 inhibitor monotherapy. (Pubmed Central) -  Aug 6, 2024   
    A 55-year-old woman with a moderately differentiated cutaneous squamous cell carcinoma (cSCC) of the upper lip experienced initial tumour growth and new lymphadenopathy after starting immunotherapy with Cemiplimab, but achieved complete remission with no adverse events after five infusions. This case underscores the potential of immunotherapy for cSCC in sensitive head and neck areas and illustrates the phenomenon of pseudoprogression, where apparent tumour growth can occur before clinical improvement.
  • ||||||||||  Arzerra (ofatumumab) / Novartis, Genmab, Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Roche
    Journal:  Enhancement of complement-dependent cytotoxicity by linking factor-H derived short consensus repeats 19-20 to CD20 antibodies. (Pubmed Central) -  Aug 6, 2024   
    Lysis of CLL cells was not affected by the depletion of NK cells, suggesting that antibody-dependent cellular cytotoxicity plays a minor role in this context. Overall, this study emphasizes the crucial role of CDC in the elimination of CLL cells by mAbs and introduces a novel approach for enhancing CDC by directly fusing fH SCR1920 with mAbs.
  • ||||||||||  Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis
    Enrollment open, Enrollment change, Trial initiation date, Metastases:  Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. (clinicaltrials.gov) -  Aug 6, 2024   
    P2,  N=45, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=30 --> 45 | Initiation date: Oct 2023 --> Aug 2024
  • ||||||||||  Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
    Enrollment open, Trial completion date, Trial primary completion date:  Atezolizumab+Bevacizumab+SBRT in Unresectable HCC (clinicaltrials.gov) -  Aug 6, 2024   
    P1,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Jan 2026 --> Aug 2026 | Trial primary completion date: Jan 2024 --> Aug 2024
  • ||||||||||  TQB2928 / Sino Biopharm, Anniko (penpulimab) / Akesobio, Sino Biopharm
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases:  TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors. (clinicaltrials.gov) -  Aug 6, 2024   
    P1,  N=3, Terminated, 
    Active, not recruiting --> Completed N=114 --> 3 | Trial completion date: Mar 2028 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jul 2024; Based on the current status of the same target research and the company's overall layout in the field of tumors, the early termination was determined after full communication with the principal investigator of the group leader unit.
  • ||||||||||  Phase classification:  FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) -  Aug 6, 2024   
    P2,  N=716, Recruiting, 
    N=114 --> 3 | Trial completion date: Mar 2028 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Jul 2024; Based on the current status of the same target research and the company's overall layout in the field of tumors, the early termination was determined after full communication with the principal investigator of the group leader unit. Phase classification: P1/2 --> P2
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly
    Trial completion date, Trial primary completion date:  Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer (clinicaltrials.gov) -  Aug 6, 2024   
    P1/2,  N=20, Recruiting, 
    Phase classification: P1/2 --> P2 Trial completion date: Nov 2022 --> Dec 2024 | Trial primary completion date: Nov 2022 --> Dec 2024
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Unexpected Ulnar Nerve Injury in a Brief, Straightforward Case (Exhibit Hall) -  Aug 6, 2024 - Abstract #ASA2024ASA_5557;    
    A 44-year-old female enrolled in clinical trial IRB 201036 for metastatic colon cancer and receiving pembrolizumab, presents with abdominal pain and distension...She has a normal body habitus, is positioned supine with her arms extended and padded during the one-hour surgical procedure. Upon awakening, the patient reports unexpected weakness and numbness in her right upper extremity.
  • ||||||||||  Rituxan (rituximab) / Roche
    Effect of Local Anesthetics and Wound Care in Chemotherapy-Induced Wound Ulcers: Case Report Analysis of a Non-Hodgkin's Lymphoma Patient (Exhibit Hall) -  Aug 6, 2024 - Abstract #ASA2024ASA_5309;    
    Subsequently, the patient developed a purpuric morbilliform eruption, likely linked to the chemotherapy treatment, and was treated at the wound clinic for bilateral lower extremity vasculitis wounds. Managed with Cetacaine spray and debridement, the case report will present a comprehensive analysis of the importance and effectiveness of local anesthetics and wound care in the healing process of anticancer chemotherapy-induced wound ulcers and other chronic leg ulcers.
  • ||||||||||  Simulect (basiliximab) / Novartis
    Basilixumab Induced Pulmonary Edema Required ECMO Post Kidney Transplant (Exhibit Hall) -  Aug 6, 2024 - Abstract #ASA2024ASA_5169;    
    On postoperative day 3, he developed respiratory distress following the second dose of induction with basiliximab...Despite initiation of high dose furosemide and progression to intubation with addition of neuromuscular blockade to assist with ventilator compliance, there was continued difficulty ventilating the patient...Patient instability prompted cannulation for VV-ECMO. His respiratory status improved, with P:F ratio 397, and he was decannulated on ECMO day 4.